stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Revenue
Celldex Therapeutics, Inc.'s revenue for fiscal 2025 was $1.5M, down 78.0% from $7.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $887.0K. Over the past ten years it has ranged from $1.5M (fiscal 2025) to $12.7M (fiscal 2017) — the current reading is the lowest in ten years. Celldex Therapeutics, Inc. ranks 318th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.5M | (77.99%) |
| FY2024 | $7.0M | 1.99% |
| FY2023 | $6.9M | 192.02% |
| FY2022 | $2.4M | (49.32%) |
| FY2021 | $4.7M | (37.30%) |
| FY2020 | $7.4M | 107.61% |
| FY2019 | $3.6M | (62.54%) |
| FY2018 | $9.5M | (25.15%) |
| FY2017 | $12.7M | 87.78% |
| FY2016 | $6.8M | 23.83% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $22.0K | 46.67% |
| Mar 2026 | $15.0K | (87.50%) |
| Dec 2025 | $120.0K | (83.56%) |
| Jun 2025 | $730.0K | 5.04% |
| 41 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| ADMA ADMA Biologics Inc compare | $519.2M |
| VCEL Vericel Corporation compare | $324.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $321.7M |
| PVLA Palvella Therapeutics, Inc. compare | $41.6M |
| IMNM Immunome, Inc. compare | $12.6M |
| CLDX Celldex Therapeutics, Inc. | $887.0K |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CLDX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement